Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Deborah A. Robins"'
Autor:
Lori I. Robins, Erika K. Keim, Deborah B. Robins, John S. Edgar, John S. Meschke, Philip R. Gafken, Jeffrey F. Williams
Publikováno v:
ACS Omega, Vol 6, Iss 51, Pp 35593-35599 (2021)
Externí odkaz:
https://doaj.org/article/7c6dc9ca327b4ce585bd8fc431a04f61
Autor:
Deborah Ahn Robins, Nina H. Grootendorst-van Mil, Chin-Kuo Chang, David Chandran, Hitesh Shetty, Jyoti Sanyal, James H. MacCabe, Hannah Cohen, Robert Stewart, Frederike Schirmbeck, Lieuwe de Haan, Richard D. Hayes
Publikováno v:
Journal of clinical psychiatry, 83(6):21m14010. Physicians Postgraduate Press Inc.
Ahn Robins, D, Grootendorst-van, N H, Chang, C K, Chandran, D, Shetty, H, Sanyal, J, MacCabe, J H, Cohen, H, Stewart, R, Schirmbeck, F, de Haan, L & Hayes, R D 2022, ' Prevalence and Correlates of Obsessive-Compulsive Symptoms in Individuals With Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder ', The Journal of Clinical Psychiatry, vol. 83, no. 6, 21m14010 . https://doi.org/10.4088/JCP.21m14010
Ahn Robins, D, Grootendorst-van, N H, Chang, C K, Chandran, D, Shetty, H, Sanyal, J, MacCabe, J H, Cohen, H, Stewart, R, Schirmbeck, F, de Haan, L & Hayes, R D 2022, ' Prevalence and Correlates of Obsessive-Compulsive Symptoms in Individuals With Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder ', The Journal of Clinical Psychiatry, vol. 83, no. 6, 21m14010 . https://doi.org/10.4088/JCP.21m14010
Objective: Although frequently reported in psychosis, obsessive-compulsive symptoms (OCS) are often not recognized and thus undertreated. We aimed to estimate the prevalence of OCS and obsessive-compulsive disorder (OCD) in patients with schizophreni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8beadb7d2db8f6870e6a765f0256bdf1
https://pure.amc.nl/en/publications/prevalence-and-correlates-of-obsessivecompulsive-symptoms-in-individuals-with-schizophrenia-schizoaffective-disorder-or-bipolar-disorder(270238b7-ea93-48a2-9ab3-5861aff28b87).html
https://pure.amc.nl/en/publications/prevalence-and-correlates-of-obsessivecompulsive-symptoms-in-individuals-with-schizophrenia-schizoaffective-disorder-or-bipolar-disorder(270238b7-ea93-48a2-9ab3-5861aff28b87).html
Autor:
CHARLES BENSON, LAI-SAN THAM, YU DU, SIREL GURBUZ, DEBORAH A. ROBINS, KIEREN J. MATHER, CHENG CAI TANG, MELISSA K. THOMAS
Publikováno v:
Diabetes. 71
LY is an acylated peptide analog of oxyntomodulin, a dual glucagon and GLP-1 receptor agonist. We conducted 2 randomized, double-blind, phase 1 multiple ascending subcutaneous dosing studies in healthy subjects (S1, NCT03325387) and in T2D patients (
Publikováno v:
Diabetes. 71
Background: LY3502970 (LY) is a novel, highly potent, orally bioavailable nonpeptide GLP-1 receptor agonist (RA) , and a potential alternative to injectable therapies or oral peptides whose absorption is affected by food or water intake. Objectives o
Autor:
Olivier Benichou, Tamer Coskun, Malgorzata D. Gonciarz, Parag Garhyan, Andrew C. Adams, Yu Du, James D. Dunbar, Jennifer A. Martin, Kieren J. Mather, Richard T. Pickard, Vincent L. Reynolds, Deborah A. Robins, Simbarashe P. Zvada, Paul J. Emmerson
Publikováno v:
Cell Metabolism. 35:274-286.e10
Autor:
Ross Bray, Amir Nikooienejad, Deborah A. Robins, Axel Haupt, Kevin L. Duffin, Jonathan M. Wilson, Melissa K. Thomas, Zvonko Milicevic, Xuewei Cui
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Context Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulagl
Autor:
Jonathan M. Wilson, Axel Haupt, Deborah A. Robins, Marja-Riitta Taskinen, William C. Roell, Giacomo Ruotolo, Jeffrey S. Riesmeyer, Amir Nikooienejad, Kevin L. Duffin
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein-related biomarkers were measured post hoc in available samples from the same study. Materials and M
Autor:
Axel Haupt, Xuewei Cui, Michael A. Nauck, Shweta Urva, Joanna Van, Zvonko Milicevic, Deborah A. Robins, Ross Bray, Juan P. Frias, Charles Benson
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To assess the efficacy and tolerability of tirzepatide treatment using three different dose‐escalation regimens in patients with type 2 diabetes. Materials and Methods In this double‐blind, placebo‐controlled study, patients were randomized
Autor:
Jonathan M. Wilson, Axel Haupt, Giacomo Ruotolo, Amy L. Cox, Deborah A. Robins, Yanzhu Lin, Lenden M. Bowsman, M. Jane Luo, Gary Considine, Kevin L. Duffin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b8d9197fc372977409511dd3e0b5603
https://doi.org/10.1111/dom.14553/v2/response1
https://doi.org/10.1111/dom.14553/v2/response1
Autor:
Giacomo Ruotolo, Amy L. Cox, Lenden M. Bowsman, Kevin L. Duffin, Jonathan M. Wilson, Yanzhu Lin, M. Jane Luo, Gary Considine, Deborah A. Robins, Axel Haupt
Publikováno v:
Diabetes, obesitymetabolism. 24(1)
In a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and bo